Lv44
750 积分 2025-03-17 加入
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
6小时前
已完结
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
1天前
已完结
Weight regain after bariatric surgery: A systematic review and meta-analysis of observational studies
2天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial
1个月前
已完结
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
1个月前
已完结
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已关闭
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
1个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1个月前
已完结
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial
1个月前
已关闭
皖公网安备34019202002308
